Precision Oncology Market – Global Market Size, Strategic Growth Drivers, Risk Assessment Framework, Regulatory Landscape Review, Competitive Intensity Mapping & Long-Term Industry Outlook to 2032
Overview
Global Precision Oncology Market is worth USD 118.8 billion in 2025 and is estimated to grow at a CAGR of 9.9% in the forecasted period. The forecasted revenue hints at a growth of around 230.40 billion USD by 2032.
Global Precision Oncology Market Overview
The Global Precision Oncology Market consists of advanced diagnostic, genomic, and molecular technologies that are used to tailor cancer prevention, diagnosis, prognosis, and treatment according to the genetic and molecular characteristics of individual patients and their tumors. The market includes genomic profiling, biomarker testing, liquid biopsy, companion diagnostics, next-generation sequencing (NGS), targeted therapies, immunotherapies, and data-driven treatment selection. Precision oncology enables clinicians to select more individualized treatment strategies and reduce reliance on therapies that may prove less effective for specific patient populations.
The growing global cancer burden is a major factor supporting demand for precision oncology solutions. Around 20.6 million new cancer cases are diagnosed globally and 9.8 million people died from cancer in 2024. The figures cover 34 cancer types across 186 countries and highlight the expanding global burden of cancer, strengthening the need for more precise approaches to diagnosis and treatment. The growing burden is expected to support demand for precision oncology solutions, including genomic profiling, biomarker testing, next-generation sequencing, liquid biopsy, and targeted therapies that enable more individualized cancer management.
The technological innovation are transforming market through the convergence of NGS, artificial intelligence(AI),multi-omics, liquid biopsy, and real-world data analytics. These technologies are improving the identification of actionable biomarkers and supporting more informed treatment decisions across different cancer types. The increasing development of companion diagnostics is also strengthening the connection between molecular testing and targeted drug selection. North America is the region , supported by advanced healthcare infrastructure, high adoption of genomic testing, strong pharmaceutical and biotechnology investment, and the presence of established companies such as Illumina, Thermo Fisher Scientific, Foundation Medicine, Guardant Health, and Tempus, making it the leader in the market. Europe benefits from expanding genomic medicine initiatives and precision healthcare programs, while Asia Pacific is expected to offer significant growth opportunities due to rising cancer incidence, improving healthcare infrastructure, and growing investments in biotechnology and genomic medicine. Ultimately, the market is being reshaped by the convergence of genomics, AI, precision diagnostics, targeted therapies, and personalized medicine, with the industry increasingly moving toward earlier molecular detection and individualized cancer treatment.
To know about the Research Methodology :- Request Free Sample Report
Precision Oncology Market Dynamics:
Rising Global Cancer Burden and Increasing Demand for Personalized Treatment are Driving Market Growth
The growing prevalence of cancer is increasing demand for more effective and individualized approaches to diagnosis and treatment. Recent 9.8 million cancer deaths globally in 2024, highlighting the need for improved treatment strategies. Precision oncology enables clinicians to identify tumor-specific genetic alterations and biomarkers and select therapies that are more closely matched to individual patients. The increasing use of genomic profiling, biomarker testing, and targeted therapies is therefore supporting the expansion of precision oncology across multiple cancer types.
Advances in Next-Generation Sequencing and Molecular Diagnostics are Creating New Market Opportunities
Rapid advances in next-generation sequencing (NGS), liquid biopsy, multi-omics, and companion diagnostics are expanding the ability to detect and characterize cancer at the molecular level. These technologies enable healthcare providers to identify actionable mutations and monitor treatment response, while liquid biopsy is creating opportunities for less-invasive cancer profiling and disease monitoring. The growing integration of these technologies into clinical oncology is creating opportunities for diagnostic companies, pharmaceutical manufacturers, and biotechnology firms to develop more precise and personalized cancer-care solutions.
High Cost of Genomic Testing and Limited Access to Advanced Diagnostics are Restraining Market Expansion
The high cost associated with genomic sequencing, molecular diagnostics, specialized laboratory infrastructure, and targeted therapies can limit the adoption of precision oncology, particularly in developing and cost-sensitive healthcare markets. Access to advanced testing also varies considerably between countries and healthcare systems. Limited reimbursement coverage, a shortage of trained professionals, and differences in healthcare infrastructure can further restrict the availability of precision oncology services. These factors remain important barriers to the widespread integration of precision medicine into routine cancer care.
Complex Data Management and Regulatory Challenges Remain Key Industry Challenges
Precision oncology generates large volumes of complex genomic and clinical data, creating challenges related to data interpretation, interoperability, privacy, cybersecurity, and clinical decision-making. Integrating genomic information with electronic health records and real-world clinical data requires advanced analytical infrastructure and standardized data systems. In addition, regulatory requirements for companion diagnostics, biomarker-based therapies, and AI-supported clinical tools can increase development timelines and costs. Ensuring the clinical validity and reliability of molecular testing remains critical for broader adoption.
Precision Oncology Market Trends:
- AI and Machine Learning are Transforming Precision Cancer Care - AI and machine learning are increasingly being applied to genomic data analysis, biomarker discovery, treatment selection, and patient stratification. AI-based tools can help researchers analyze complex molecular datasets and identify patterns that may be difficult to detect through conventional approaches. The integration of AI with precision oncology is supporting faster interpretation of genomic information and enabling more data-driven treatment decisions.
- Liquid Biopsy is Emerging as a Key Precision Oncology Technology - Liquid biopsy is gaining momentum as a minimally invasive approach for detecting and monitoring cancer through biomarkers circulating in blood and other biological fluids. The technology is increasingly being explored for early cancer detection, molecular profiling, treatment monitoring, and detection of minimal residual disease. As sensitivity and accuracy improve, liquid biopsy is expected to become increasingly integrated with traditional tissue-based diagnostics.
- Multi-Omics is Expanding the Scope of Personalized Cancer Treatment - The integration of genomics, transcriptomics, proteomics, metabolomics, and epigenomics is becoming an important trend in precision oncology. Multi-omics approaches provide a more comprehensive understanding of tumor biology and can help identify complex disease mechanisms and potential therapeutic targets. This is supporting the development of more sophisticated patient stratification and treatment strategies.
- Companion Diagnostics and Targeted Therapies are Becoming Increasingly Interconnected - The development of companion diagnostics alongside targeted cancer therapies is becoming increasingly important for identifying patients most likely to benefit from specific treatments. Pharmaceutical and diagnostic companies are increasingly collaborating to develop biomarker-based treatment pathways, strengthening the connection between molecular testing and therapeutic decision-making. This trend is supporting the shift toward more personalized treatment approaches and improving the potential for targeted therapies to reach appropriate patient populations.
Technology Landscape for Precision Oncology Market
The Precision Oncology Market is being transformed by advanced technologies that enable more accurate cancer diagnosis, molecular profiling, patient stratification, and personalized treatment selection. NGS and liquid biopsy are expanding the ability to identify actionable genetic alterations, while AI and bioinformatics support the analysis of complex genomic and clinical datasets. Meanwhile, biomarker testing and companion diagnostics are strengthening the adoption of targeted therapies by identifying patients most likely to respond to specific treatments.
Precision Oncology Market Segmentation:
The Precision Oncology Market, by product type, is divided into Diagnostics and Therapeutics.
The Therapeutics segment dominated the Precision Oncology Market in 2025 and is expected to maintain its leading position throughout the forecast period. The segment benefits from the increasing adoption of targeted therapies, immunotherapies, and biomarker-driven treatments designed to address specific molecular characteristics of tumors. The growing development of companion diagnostics is also strengthening the connection between molecular testing and targeted drug selection, enabling pharmaceutical companies to identify patient populations most likely to respond to specific treatments. Increasing investments in oncology drug development and the expanding pipeline of biomarker-based therapies are expected to support continued growth. While, the Diagnostics segment is expected to witness strong growth as genomic profiling, next-generation sequencing (NGS), liquid biopsy, and molecular biomarker testing become increasingly integrated into cancer diagnosis and treatment selection. However, therapeutics is expected to remain the dominant product type due to the high value associated with targeted cancer treatments and the continued expansion of precision-based oncology drug pipelines.
The Precision Oncology Market, by cancer type, is divided into Breast Cancer, Lung Cancer, Cervical Cancer, Colorectal Cancer, Prostate Cancer, and Others.
The Lung Cancer segment dominated the Precision Oncology Market in 2025 and is expected to maintain its leading position during the forecast period. Lung cancer has a particularly strong connection with precision oncology because molecular testing is routinely used to identify actionable biomarkers that can guide treatment selection. Biomarkers and genetic alterations involving EGFR, ALK, ROS1, BRAF, KRAS, and MET, among others, have contributed to the expansion of targeted treatment approaches. The Breast Cancer segment also represents a major application area, supported by established biomarker testing for targets such as HER2 and hormone receptors, while the colorectal cancer segment is benefiting from increasing molecular profiling and biomarker-guided treatment strategies. Prostate cancer is also gaining importance as genomic and molecular testing becomes increasingly relevant to treatment selection and risk assessment. Cervical cancer represents an emerging opportunity, particularly as molecular diagnostics and biomarker research continue to advance.
Precision Oncology Market Regional Insights:
North America remains a leading region in the Precision Oncology Market, supported by advanced healthcare infrastructure, high adoption of genomic testing, strong pharmaceutical and biotechnology investment, and established precision-medicine ecosystems. The region's large cancer burden also creates substantial demand for molecular diagnostics and targeted therapies. North America accounted for nearby 13% of global cancer cases, reinforcing the need for advanced cancer diagnostics and treatment. The region benefits from the presence of established companies such as Illumina, Thermo Fisher Scientific, Foundation Medicine, Guardant Health, and Tempus, which are active across genomic profiling, liquid biopsy, molecular diagnostics, and data-driven oncology.
Europe represents another significant market, driven by growing adoption of genomic medicine, national cancer-control programs, and increasing integration of molecular diagnostics into clinical oncology. Europe accounted for 21.0% of global cancer cases and 20.0% of cancer deaths in 2024, despite representing only around 9% of the global population. This disproportionately high cancer burden is supporting demand for precision diagnostics and targeted therapies. The region's market is further supported by established pharmaceutical and diagnostics companies, including Roche, AstraZeneca, Novartis, and BioNTech, alongside expanding investments in genomics and personalized medicine.
Asia Pacific is expected to offer significant growth opportunities as the region carries the largest share of the global cancer burden while healthcare systems increasingly invest in advanced diagnostics and oncology infrastructure. In 2024, Asia accounted for 50.7% of global cancer cases and 56.5% of cancer deaths, creating substantial long-term demand for improved cancer diagnosis and treatment. The region is also experiencing increasing investments in genomic testing, NGS, biotechnology, and targeted therapies, particularly in China, Japan, South Korea, and India. Key companies and technology providers include BGI Genomics, Burning Rock Biotech, Novogene, Illumina, and Thermo Fisher Scientific. The combination of a large patient population, rising cancer burden, improving healthcare infrastructure, and expanding access to molecular diagnostics positions Asia Pacific as a major growth opportunity.
Latin America represents an emerging opportunity, supported by increasing cancer incidence, growing healthcare expenditure, and gradual expansion of molecular diagnostics and genomic testing. However, differences in healthcare access, reimbursement, testing infrastructure, and affordability of precision therapies continue to limit adoption compared with North America and Europe. Middle East & Africa also offer long-term potential as healthcare systems invest in oncology infrastructure and advanced diagnostics, although limited access to specialized genomic testing and high treatment costs remain key challenges. Overall, North America remains a leading precision oncology market, Europe benefits from a high cancer burden and strong healthcare systems, while Asia Pacific presents substantial growth potential due to its disproportionately large cancer burden and expanding precision-medicine capabilities. IARC projects that global cancer incidence could reach 34.4 million cases by 2050, a 67% increase from 2024, with the largest proportional increases expected in lower-HDI countries, further highlighting the future need to expand access to precision oncology technologies globally.
Precision Oncology Market Recent Developments:
| Month & Year | Recent Development |
| January 2025 | Roche expanded its precision oncology ecosystem through continued development of comprehensive genomic profiling and companion diagnostic solutions, supporting biomarker-driven treatment selection across multiple cancer types. |
| February 2025 | Guardant Health continued expanding its liquid-biopsy portfolio, strengthening the role of blood-based genomic testing in cancer screening, treatment selection, and disease monitoring. |
| March 2025 | Illumina continued advancing next-generation sequencing technologies for oncology, supporting the broader adoption of comprehensive genomic profiling and molecular diagnostics in clinical cancer care. |
| April 2025 | Tempus expanded the application of AI and clinical data analytics in precision medicine, combining genomic information with clinical datasets to support more personalized cancer treatment decisions. |
| May 2025 | Foundation Medicine continued strengthening its comprehensive genomic profiling capabilities, supporting the identification of actionable biomarkers and the use of targeted therapies across cancer types. |
| June 2025 | Thermo Fisher Scientific continued expanding its oncology-focused NGS and companion diagnostic capabilities, supporting pharmaceutical and clinical laboratories in biomarker identification and precision treatment strategies. |
| 2025 | Pharmaceutical and diagnostic companies increasingly expanded partnerships around companion diagnostics, accelerating the development of biomarker-driven therapies and testing solutions that identify patients most likely to benefit from specific treatments. |
| 2025–2026 | AI and machine learning increasingly became integrated into precision oncology workflows, particularly for genomic data interpretation, biomarker discovery, patient stratification, and treatment decision support. |
| 2025–2026 | Liquid biopsy gained increasing attention as a precision oncology technology, with companies focusing on applications including early cancer detection, treatment monitoring, recurrence detection, and minimal residual disease assessment. |
| 2025–2026 | Multi-omics and real-world data integration emerged as important competitive areas, with companies combining genomic, clinical, and other biological datasets to improve patient stratification and identify new therapeutic targets. |
Precision Oncology Market Competitive Landscape:
The Precision Oncology Market is highly competitive and innovation-driven, with competition spanning pharmaceutical companies, biotechnology firms, molecular diagnostics providers, genomic sequencing companies, and liquid-biopsy specialists. Leading players include Roche, AstraZeneca, Novartis, Merck & Co., Inc., Bristol Myers Squibb, Illumina, Thermo Fisher Scientific, Foundation Medicine, Guardant Health, Tempus, Exact Sciences, Bio-Rad Laboratories, and Qiagen. Global pharmaceutical companies primarily compete through targeted therapies, immunotherapies, biomarker-driven drug development, and companion diagnostics, while diagnostic and genomics companies compete on sequencing accuracy, testing speed, clinical validation, biomarker coverage, and data interpretation capabilities. The competitive landscape is increasingly shaped by strategic partnerships between pharmaceutical and diagnostic companies, as successful precision oncology depends on linking molecular testing with appropriate targeted treatments.
Competition is also becoming more focused on comprehensive genomic profiling, liquid biopsy, AI-powered cancer analytics, and multi-omics. Companies such as Foundation Medicine and Tempus emphasize integrated genomic and clinical data platforms, while Guardant Health and Exact Sciences are strengthening their positions in blood-based and non-invasive cancer testing. Meanwhile, pharmaceutical companies are expanding targeted therapy pipelines across lung, breast, colorectal, prostate, and other cancers. Competitive differentiation is increasingly based on clinical evidence, regulatory approvals, companion diagnostic capabilities, reimbursement coverage, turnaround time, and access to large-scale genomic datasets. The market is also witnessing increased collaboration between technology providers, healthcare institutions, and pharmaceutical companies to accelerate biomarker discovery and improve treatment selection.
Precision Oncology Market Scope: Inquire before buying
| Precision Oncology Market | |||
|---|---|---|---|
| Report Coverage | Details | ||
| Base Year: | 2025 | Forecast Period: | 2026-2032 |
| Historical Data: | 2020 to 2025 | Market Size in 2025: | 118.8 USD Bn |
| Forecast Period 2026-2032 CAGR: | 9.9% | Market Size in 2032: | 230.04 USD Bn |
| Segments Covered: | By Product Type | Diagnostics Therapeutics |
|
| By Cancer Type | Breast Cancer Lung Cancer Cervical cancer Colorectal Cancer Prostate Cancer Others |
||
| By Biomarker Type | Genomics Transcriptomics Proteomics Epigenomics Pharmacogenomics Others |
||
| By Therapy Type | Targeted Therapy Immunotherapy Hormone Therapy Chemotherapy Radiotherapy Others |
||
| By Application | Diagnostics Prognostics Therapeutics Drug Development & Clinical Trials Monitoring & Recurrence Detection Others |
||
| By End User | Pharmaceutical & Biotechnology Companies Diagnostic Centres Healthcare Data Companies Others |
||
Precision Oncology Market, by Region
North America (United States, Canada and Mexico)
Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe)
Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC)
Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A)
South America (Brazil, Argentina Rest of South America)
Precision Oncology Market Key Players:
North America
- Illumina, Inc. – United States
- Thermo Fisher Scientific Inc. – United States
- Agilent Technologies, Inc. – United States
- Foundation Medicine, Inc. – United States
- Tempus AI, Inc. – United States
- Caris Life Sciences – United States
- NeoGenomics Laboratories, Inc. – United States
- Exact Sciences Corporation – United States
- Guardant Health, Inc. – United States
- Natera, Inc. – United States
- Myriad Genetics, Inc. – United States
- Freenome Holdings, Inc. – United States
- Bristol Myers Squibb Company – United States
- Pfizer Inc. – United States
- Amgen Inc. – United States
- Merck & Co., Inc. – United States
- Eli Lilly and Company – United States
- Gilead Sciences, Inc. – United States
- AbbVie Inc. – United States
- Johnson & Johnson – United States
- Laboratory Corporation of America Holdings (Labcorp) – United States
- Flatiron Health, Inc. – United States
- PathAI, Inc. – United States
- ConcertAI – United States
- Quest Diagnostics Incorporated – United States
- Charles River Laboratories International, Inc. – United States
- IQVIA Holdings Inc. – United States
- ICON plc – United States operations
Europe
- QIAGEN N.V. – Netherlands
- F. Hoffmann-La Roche Ltd. – Switzerland
- SOPHiA GENETICS SA – Switzerland
- Oxford Nanopore Technologies plc – United Kingdom
- Eurofins Scientific SE – Luxembourg
- ANGLE plc – United Kingdom
- Biocartis NV – Belgium
- AstraZeneca plc – United Kingdom
- Novartis AG – Switzerland
- Bayer AG – Germany
- Sanofi S.A. – France
- Boehringer Ingelheim – Germany
- bioMérieux SA – France
- Owkin – France
- Paige AI, Inc. – Europe operations
- Unilabs Group – Switzerland
- Synlab Group – Germany
Asia Pacific
- BGI Genomics Co., Ltd. – China
- MGI Tech Co., Ltd. – China
- Sysmex Corporation – Japan
- Macrogen Inc. – South Korea
- Novogene Co., Ltd. – China
- Burning Rock Biotech Limited – China
- Berry Oncology Co., Ltd. – China
- Daiichi Sankyo Company, Limited – Japan
- Takeda Pharmaceutical Company Limited – Japan
- BeiGene, Ltd. – China
- Jiangsu Hengrui Pharmaceuticals Co., Ltd. – China
- Fujirebio Holdings, Inc. – Japan
- Fujitsu Limited – Japan
- NEC Corporation – Japan
- SRL Diagnostics – India
- Dr. Lal PathLabs Limited – India
- KingMed Diagnostics – China
Latin America
Others
Frequently Asked Questions:
- What is the Precision Oncology Market?
The Precision Oncology Market focuses on personalized cancer diagnosis and treatment using genomic profiling, biomarker testing, liquid biopsy, companion diagnostics, artificial intelligence, and targeted therapies to tailor treatment to individual patients. - What are the key factors driving the Precision Oncology Market?
The market is primarily driven by the increasing prevalence of cancer, growing adoption of genomic testing, advancements in next-generation sequencing (NGS), rising demand for targeted therapies, development of companion diagnostics, and increasing use of AI and data analytics in cancer care. - Which technologies are widely used in precision oncology?
Key technologies include next-generation sequencing (NGS), genomic profiling, liquid biopsy, molecular diagnostics, biomarker testing, companion diagnostics, artificial intelligence, bioinformatics, and real-world data analytics. - Which region dominates the Precision Oncology Market?
North America is generally considered a leading region due to advanced healthcare infrastructure, high adoption of genomic testing and targeted therapies, strong pharmaceutical and biotechnology industries, and the presence of major precision oncology companies. Europe and Asia Pacific are also witnessing significant growth. - What is the future outlook for the Precision Oncology Market?
The market is expected to experience strong growth as precision medicine becomes increasingly integrated into cancer diagnosis and treatment. Advances in genomic technologies, AI-driven clinical decision support, liquid biopsy, and personalized targeted therapies are expected to create new opportunities for market participants